Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology Broadens Application of ...
Highlights Potential of Fusogen Platform in Diseases like Sickle Cell Disease and Beta Thalassemia Without the Need for Conditioning Chemotherapy Sana is Incorporating its Fusogen Technology to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback